Asia Pac ECM and Index Rebal, Shenton Research

Ke Yan, CFA, FRM

An inquisitive investment analyst with background in both finance and computing. Covering ECM research, biotech, market data analytics.

Asia Pac ECM and Index Rebal

Tencent/NetEase: None Got Approval in Feb

Tencent (700 HK): Plunge Without Material Bad News, To Create Opportunity After Coming Results

Tencent (700 HK) Results on 18 March: Expected Price Action and Options Signals

Tencent/Netease: Tencent Received One, Still Ranked 1st in 2025

Tencent/Netease: Zero Approval in November Despite Game Approvals at New High

Tencent/Netease: Zero for Big Names Despite Optimism in October

Asia Pac IPO & Placement Research, China Biotech

DZT Research

DZT Research is an independent Asia Pacific equity specialist. Our quantitative research covers index rebalancing flows, alongside exchange data analytics accross Asia Pacific. On the equity capital markets side, we focus on Asia Pacific ECM, especially biotech and TMT. Our lead analyst is frequently cited by international media.

Equity Bottom-Up

<ul>
<li>China announced game approval for the January batch. The number of games approved remained at a higher level than in 2023 and 2024.</li>
<li>The pace of China game approval appears to have accelerated to the same level as pre-tightening.</li>
<li>Of the companies that we are monitoring, both Tencent and Netease got one approval.</li>
</ul>


China announced game approval for the January batch. The number of games approved remained at a higher level than in 2023 and 2024.
The pace of China game approval appears to have accelerated to the same level as pre-tightening.
Of the companies that we are monitoring, both Tencent and Netease got one approval.


Tencent/Netease: One Game for Each in Jan 2026